{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:03:08Z","timestamp":1791198188548,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2009,2,23]],"date-time":"2009-02-23T00:00:00Z","timestamp":1235347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,2,23]],"date-time":"2009-02-23T00:00:00Z","timestamp":1235347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2009,4,9]]},"DOI":"10.1038\/onc.2009.7","type":"journal-article","created":{"date-parts":[[2009,2,23]],"date-time":"2009-02-23T11:04:36Z","timestamp":1235387076000},"page":"1669-1681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Jak2 inhibition deactivates Lyn kinase through the SET\u2013PP2A\u2013SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients"],"prefix":"10.1038","volume":"28","author":[{"given":"A K","family":"Samanta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S N","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Perrotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R B","family":"Arlinghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,23]]},"reference":[{"key":"BFonc20097_CR1","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/cncr.22215","volume":"107","author":"RH Alvarez","year":"2006","unstructured":"Alvarez RH, Kantarjian HM, Cortes JE . (2006). The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107: 1918\u20131929.","journal-title":"Cancer"},{"key":"BFonc20097_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/157340607780059549","volume":"3","author":"O Bruno","year":"2007","unstructured":"Bruno O, Brullo C, Bondavalli F, Ranise A, Schenone S, Tognolini M et al. (2007). 2-Amino\/azido\/hydrazino-5-alkoxy-5H-[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological evaluation. Med Chem 3: 127\u2013134.","journal-title":"Med Chem"},{"key":"BFonc20097_CR3","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","volume":"103","author":"S Chu","year":"2004","unstructured":"Chu S, Holtz M, Gupta M, Bhatia R . (2004). BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103: 3167\u20133174.","journal-title":"Blood"},{"key":"BFonc20097_CR4","doi-asserted-by":"publisher","first-page":"34227","DOI":"10.1074\/jbc.M402290200","volume":"279","author":"Y Dai","year":"2004","unstructured":"Dai Y, Rahmani M, Corey SJ, Dent P, Grant S . (2004). A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279: 34227\u201334239.","journal-title":"J Biol Chem"},{"key":"BFonc20097_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. (2003). BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101: 690\u2013698.","journal-title":"Blood"},{"key":"BFonc20097_CR6","first-page":"5766","volume":"22","author":"NJ Donato","year":"2004","unstructured":"Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB et al. (2004). Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 22: 5766\u20135774.","journal-title":"Cancer Res"},{"key":"BFonc20097_CR7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/ng1343","volume":"36","author":"Y Hu","year":"2004","unstructured":"Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D et al. (2004). Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 36: 453\u2013461.","journal-title":"Nat Genet"},{"key":"BFonc20097_CR8","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1182\/blood.V93.12.4154","volume":"93","author":"RL Ilaria Jr","year":"1999","unstructured":"Ilaria RL Jr, Hawley RG, Van Etten RA . (1999). Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 93: 4154\u20134166.","journal-title":"Blood"},{"key":"BFonc20097_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1182\/blood-2002-02-0545","volume":"101","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S et al. (2003). Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 101: 97\u2013100.","journal-title":"Blood"},{"key":"BFonc20097_CR10","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.1093\/emboj\/cdf562","volume":"21","author":"A Klejman","year":"2002","unstructured":"Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE et al. (2002). The Src family kinase Hck couples BCR\/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 21: 5766\u20135774.","journal-title":"EMBO J"},{"key":"BFonc20097_CR11","doi-asserted-by":"publisher","first-page":"9389","DOI":"10.1128\/MCB.23.24.9389-9404.2003","volume":"23","author":"L Li","year":"2003","unstructured":"Li L, Ren CH, Tahir SA, Ren C, Thompson TC . (2003). Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine\/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 23: 9389\u20139404.","journal-title":"Mol Cell Biol"},{"key":"BFonc20097_CR12","doi-asserted-by":"publisher","first-page":"11059","DOI":"10.1074\/jbc.271.19.11059","volume":"271","author":"M Li","year":"1996","unstructured":"Li M, Makkinje A, Damuni Z . (1996). The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 271: 11059\u201311062.","journal-title":"J Biol Chem"},{"key":"BFonc20097_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cellsig.2007.11.004","volume":"20","author":"M Nawa","year":"2008","unstructured":"Nawa M, Kanekura K, Hashimoto Y, Aiso S, Matsuoka M . (2008). A novel Akt\/PKB-interacting protein promotes cell adhesion and inhibits familial amyotrophic lateral sclerosis-linked mutant SOD1-induced neuronal death via inhibition of PP2A-mediated dephosphorylation of Akt\/PKB. Cell Signal 20: 493\u2013505.","journal-title":"Cell Signal"},{"key":"BFonc20097_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","volume":"8","author":"P Neviani","year":"2005","unstructured":"Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. (2005). The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein. Cancer Cell 8: 355\u2013368.","journal-title":"Cancer Cell"},{"key":"BFonc20097_CR15","first-page":"5761","volume":"62","author":"R Nimmanapalli","year":"2002","unstructured":"Nimmanapalli R, O\u2019Bryan E, Huang M, Bali P, Burnette PK, Loughran T et al. (2002). Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res 62: 5761\u20135769.","journal-title":"Cancer Res"},{"key":"BFonc20097_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.gde.2005.11.002","volume":"16","author":"T O\u2019Hare","year":"2006","unstructured":"O\u2019Hare T, Corbin AS, Druker BJ . (2006). Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 16: 92\u201399.","journal-title":"Curr Opin Genet Dev"},{"key":"BFonc20097_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/sj.leu.2404948","volume":"22","author":"A Pardanani","year":"2008","unstructured":"Pardanani A . (2008). AK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22: 23\u201330.","journal-title":"Leukemia"},{"key":"BFonc20097_CR18","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G et al. (2007). TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L\/K mutations. Leukemia 21: 1658\u20131668.","journal-title":"Leukemia"},{"key":"BFonc20097_CR19","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.4049\/jimmunol.167.6.3391","volume":"167","author":"MK Pathak","year":"2001","unstructured":"Pathak MK, Yi T . (2001). Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol 167: 3391\u20133397.","journal-title":"J Immunol"},{"key":"BFonc20097_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/sj.bjc.6603317","volume":"95","author":"D Perrotti","year":"2006","unstructured":"Perrotti D, Neviani P . (2006). ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer 95: 775\u2013781.","journal-title":"Br J Cancer"},{"key":"BFonc20097_CR21","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/nm1127","volume":"10","author":"A Ptasznik","year":"2004","unstructured":"Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM . (2004). Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 10: 1187\u20131189.","journal-title":"Nat Med"},{"key":"BFonc20097_CR22","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/j.1460-2075.1994.tb06319.x","volume":"13","author":"L Puil","year":"1994","unstructured":"Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG et al. (1994). Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13: 764\u2013773.","journal-title":"EMBO J"},{"key":"BFonc20097_CR23","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","volume":"66","author":"AK Samanta","year":"2006","unstructured":"Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB . (2006). Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 66: 6468\u20136472.","journal-title":"Cancer Res"},{"key":"BFonc20097_CR24","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1021\/jm049470k","volume":"48","author":"EM Sandberg","year":"2005","unstructured":"Sandberg EM, Ma X, He K, Frank SJ, Ostrov DA, Sayeski PP . (2005). Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. J Med Chem 48: 2526\u20132533.","journal-title":"J Med Chem"},{"key":"BFonc20097_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","volume":"1","author":"M Sattler","year":"2002","unstructured":"Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al. (2002). Critical role for Gab2 in transformation by BCR\/ABL. Cancer Cell 1: 479\u2013492.","journal-title":"Cancer Cell"},{"key":"BFonc20097_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129\u2013141.","journal-title":"Cancer Cell"},{"key":"BFonc20097_CR27","first-page":"3426","volume":"56","author":"J Wilson-Rawls","year":"1996","unstructured":"Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB . (1996). P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Res 56: 3426\u20133430.","journal-title":"Cancer Res"},{"key":"BFonc20097_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","volume":"22","author":"S Wong","year":"2004","unstructured":"Wong S, Witte ON . (2004). The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 22: 247\u2013306.","journal-title":"Annu Rev Immunol"},{"key":"BFonc20097_CR29","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","volume":"7","author":"J Wu","year":"2008","unstructured":"Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z et al. (2008). Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib resistant chronic myelogenous leukemia cells. Blood 7: 3821\u20133829.","journal-title":"Blood"},{"key":"BFonc20097_CR30","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1038\/sj.onc.1205942","volume":"21","author":"S Xie","year":"2002","unstructured":"Xie S, Lin H, Sun T, Arlinghaus RB . (2002). Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 21: 7137\u20137146.","journal-title":"Oncogene"},{"key":"BFonc20097_CR31","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","volume":"20","author":"S Xie","year":"2001","unstructured":"Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE et al. (2001). Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20: 6188\u20136195.","journal-title":"Oncogene"},{"key":"BFonc20097_CR32","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.4049\/jimmunol.169.10.5978","volume":"169","author":"T Yi","year":"2002","unstructured":"Yi T, Pathak MK, Lindner DJ, Ketterer ME, Farver C, Borden EC . (2002). Anticancer activity of sodium stibogluconate in synergy with IFNs. J Immunol 169: 5978\u20135985.","journal-title":"J Immunol"},{"key":"BFonc20097_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/blood-2006-03-013250","volume":"109","author":"A Yokota","year":"2007","unstructured":"Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K et al. (2007). INNO-406, a novel BCR-ABL\/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 109: 306\u2013314.","journal-title":"Blood"},{"key":"BFonc20097_CR34","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/107999001750277844","volume":"21","author":"N Yokoyama","year":"2001","unstructured":"Yokoyama N, Reich NC, Miller WT . (2001). Involvement of protein phosphatase 2A in the interleukin-3-stimulated Jak2-Stat5 signaling pathway. J Interferon Cytokine Res 21: 369\u2013378.","journal-title":"J Interferon Cytokine Res"},{"key":"BFonc20097_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0003-9861(03)00333-3","volume":"417","author":"N Yokoyama","year":"2003","unstructured":"Yokoyama N, Reich NC, Miller WT . (2003). Determinants for the interaction between Janus kinase 2 and protein phosphatase 2A. Arch Biochem Biophys 417: 87\u201395.","journal-title":"Arch Biochem Biophys"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc20097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc20097","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc20097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T17:06:21Z","timestamp":1647882381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc20097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,23]]},"references-count":35,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2009,4,9]]}},"alternative-id":["BFonc20097"],"URL":"https:\/\/doi.org\/10.1038\/onc.2009.7","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,23]]},"assertion":[{"value":"26 September 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}